Summarized by Masters of Longevity from Longevity Technology.
Interim six-month Phase I/II data showed fewer composite events versus controls.
Key Takeaways
- Nine treated patients had two composite events versus eight external events.
- The comparison showed a 42% relative risk reduction in composite outcomes.
- Biomarker analyses showed reduced inflammation and markers of fibrogenesis.
